← All trials
NCT05271162
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2022
- Primary completion
- Jan 1, 2028
- Completion date
- Feb 1, 2028
- First posted
- Mar 8, 2022
- Last posted
- Mar 8, 2022
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Curie InstituteLead sponsor
- Curie InstituteReponsible party - principal investigator
- Maria Sklodowska Curie Children's HospitalOverall official - principal investigator
- Government of PolandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.